Literature DB >> 26769769

FCR holds up to the test of time: CLL8 follow-up.

Jennifer A Woyach1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26769769     DOI： 10.1182/blood-2015-11-678557

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  3 in total

Review 1.  On the architecture of translational research designed to control chronic lymphocytic leukemia.

Authors:  Michael Hallek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.

Authors:  Jose D Sandoval-Sus; Julio C Chavez; Samir Dalia; Syeda Mahrukh Hussnain Naqvi; Chetasi Talati; Lisa Nodzon; Mohamed A Kharfan-Dabaja; Javier Pinilla-Ibarz
Journal:  Leuk Lymphoma       Date:  2017-06-22

Review 3.  Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib.

Authors:  Ankit Shah; Jacqueline C Barrientos
Journal:  Onco Targets Ther       Date:  2021-03-25       Impact factor: 4.147
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.